.... and what's more, the following suggests that if the science works in humans as it did in the animal models, our CAR-T-CDH17 therapy could get the monopoly on the Colorectal, various NET and a sizeable chunk of the Gastric Cancer markets. With the percentage of NET tumours expressing CDH17 protein being 100%, and the presence of the same protein in healthy tissue being hidden from detection, essentially means that our therapy has up to a potential 100% target rate within this area of unmet need. It also suggests to me, the diagnostic process is simplified (no need for a repertoire of biomarkers to determine a NET patient's suitability for our treatment). Its going to come down to how well it does its job in destroying 100% of the vulnerable NET tumours, 98% of Colorectal and 48% of Gastric Tumours.... ie. its efficacy rate. Bring on the data, please!
Add to My Watchlist
What is My Watchlist?
